MRI-guided Stereotactic Body Radiation Therapy

RADIATION4 trials

Sponsors

Jonsson Comprehensive Cancer Center, City of Hope Medical Center

Conditions

Localized Prostate AdenocarcinomaMetastatic Malignant Solid NeoplasmProstate AdenocarcinomaStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8

Unknown Phase

CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study

Active, not recruitingNCT04384770

Jonsson Comprehensive Cancer CenterProstate Adenocarcinoma

Start: 2020-05-12End: 2028-04-01Updated: 2026-05-11

Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

RecruitingNCT07276438

Jonsson Comprehensive Cancer CenterLocalized Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8 +1

Start: 2025-12-01End: 2032-12-31Target: 186Updated: 2026-02-05

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Tumors, ONE SHOT Trial

Not yet recruitingNCT07671768

Jonsson Comprehensive Cancer CenterMetastatic Malignant Solid Neoplasm

Start: 2026-12-01End: 2038-12-01Target: 25Updated: 2026-08-24

Magnetic Resonance-Guided Stereotactic Body Radiation Therapy for the Treatment of Prostate Cancer

Not yet recruitingNCT07769372

City of Hope Medical CenterStage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8 +2

Start: 2027-01-01End: 2029-03-09Target: 20Updated: 2026-08-17

Related Papers

Dosimetric Comparison of Magnetic Resonance Imaging Guided Versus Reduced Margin Computed Tomography Guided Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Post Hoc Analysis of a Phase 3 Trial.

2025-06-05

Validation and Derivation of miRNA-Based Germline Signatures Predicting Radiation Toxicity in Prostate Cancer.

2025-06-011 citations

Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial

European Urology2024-11-1321 citations

PROSTOX, a signature of late GU toxicity after SBRT radiotherapy in MIRAGE, a prospective trial.

Journal of Clinical Oncology2024-06-01

(016) Sexual Health Toxicity Following MRI-Guided versus CT-guided Prostate SBRT

The Journal of Sexual Medicine2024-02-01

Quantifying Intrafraction Motion and the Impact of Gating for Magnetic Resonance Imaging-Guided Stereotactic Radiation therapy for Prostate Cancer: Analysis of the Magnetic Resonance Imaging Arm From the MIRAGE Phase 3 Randomized Trial.

2023-12-3014 citations

Dosimetric predictors for genitourinary toxicity in MR‐guided stereotactic body radiation therapy (SBRT): Substructure with fraction‐wise analysis

Medical Physics2023-12-066 citations

Magnetic Resonance Imaging–Guided vs Computed Tomography–Guided Stereotactic Body Radiotherapy for Prostate Cancer

JAMA Oncology2023-01-12267 citations

Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): Interim analysis of a phase III randomized trial.

Journal of Clinical Oncology2022-02-1630 citations

Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial

BMC Cancer2021-05-1144 citations